Amalgamated Bank Acquires 238 Shares of Repligen Co. (NASDAQ:RGEN)

Amalgamated Bank lifted its stake in Repligen Co. (NASDAQ:RGEN) by 1.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,114 shares of the biotechnology company’s stock after acquiring an additional 238 shares during the period. Amalgamated Bank’s holdings in Repligen were worth $3,615,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Creative Planning grew its position in Repligen by 32.6% in the 3rd quarter. Creative Planning now owns 5,123 shares of the biotechnology company’s stock worth $762,000 after purchasing an additional 1,259 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 127 shares during the period. International Assets Investment Management LLC grew its position in Repligen by 15,586.5% during the third quarter. International Assets Investment Management LLC now owns 40,628 shares of the biotechnology company’s stock worth $6,046,000 after buying an additional 40,369 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Repligen by 892.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,716 shares of the biotechnology company’s stock valued at $1,856,000 after acquiring an additional 11,435 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in Repligen by 133.2% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 4,009 shares of the biotechnology company’s stock valued at $597,000 after acquiring an additional 2,290 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

Shares of Repligen stock opened at $159.26 on Friday. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $203.13. The firm’s 50-day moving average price is $155.88 and its two-hundred day moving average price is $148.70. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $8.92 billion, a price-to-earnings ratio of -312.27, a P/E/G ratio of 4.54 and a beta of 0.99.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. On average, equities analysts predict that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. StockNews.com downgraded shares of Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. JPMorgan Chase & Co. raised their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Finally, TD Cowen assumed coverage on shares of Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $181.00.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.